WO1999044583A3 - Methods and devices for modulating the immune response - Google Patents

Methods and devices for modulating the immune response Download PDF

Info

Publication number
WO1999044583A3
WO1999044583A3 PCT/US1999/004637 US9904637W WO9944583A3 WO 1999044583 A3 WO1999044583 A3 WO 1999044583A3 US 9904637 W US9904637 W US 9904637W WO 9944583 A3 WO9944583 A3 WO 9944583A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
immune response
immune
mammal
devices
Prior art date
Application number
PCT/US1999/004637
Other languages
French (fr)
Other versions
WO1999044583A2 (en
Inventor
Anthony Cerami
Carla Cerami
Cohava Gelber
David Dove
Original Assignee
Applied Vaccine Technologies C
Anthony Cerami
Carla Cerami
Cohava Gelber
David Dove
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Vaccine Technologies C, Anthony Cerami, Carla Cerami, Cohava Gelber, David Dove filed Critical Applied Vaccine Technologies C
Priority to EP99912252A priority Critical patent/EP1066028A2/en
Priority to BR9908466-0A priority patent/BR9908466A/en
Priority to CA002322435A priority patent/CA2322435A1/en
Priority to IL138207??A priority patent/IL138207A0/en
Priority to HU0101076A priority patent/HUP0101076A2/en
Priority to JP2000534186A priority patent/JP2003523308A/en
Priority to KR1020007009699A priority patent/KR20010041528A/en
Priority to AU30667/99A priority patent/AU756951B2/en
Publication of WO1999044583A2 publication Critical patent/WO1999044583A2/en
Publication of WO1999044583A3 publication Critical patent/WO1999044583A3/en
Priority to NO20004349A priority patent/NO20004349L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Abstract

The present invention provides methods and devices for inducing, stimulating, blocking and reducing the immune response of a mammal to an antigen, using an implantable device which exposes the antigen in a controlled fashion to cells of the immune system. The device comprises a porous matrix contained within a perforated, impermeable container. By manipulating the bioavailability of antigen within the device, and the timing of introduction of antigen into the device relative to the time of implantation of the device within the mammal, a robust and long-term response can be induced against an antigen, or an existing or potential immune response can be down regulated or blocked. The methods and devices can be used for therapeutic vaccination, and in non-exposed mammals for prophylactic vaccination. Immunity can be cellular, humoral, or mucosal. Suppression of the immune response is useful for the treatment or prophylaxis of such conditions as allergies, autoimmune disease, and in tolerizing mammals to suppress an immune response to transplant antigens. The device can also be used for harvesting immune cells for later reintroduction into the mammal, and for preparing immune serum and hybridomas.
PCT/US1999/004637 1998-03-02 1999-03-02 Methods and devices for modulating the immune response WO1999044583A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP99912252A EP1066028A2 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
BR9908466-0A BR9908466A (en) 1998-03-02 1999-03-02 Process to modulate the immune response, in a mammal, to an antigen, implantable device to modulate an immune response to an antigen, and, processes to obtain immune cells from a mammal, for immunization of a mammal with an antigen, for the production of hybridomas producing human monoclonal antibodies against a pre-selected antigen, to transfect a mammal's immune cells with genetic material, and for the treatment or prophylaxis of a disease or condition caused by an immune response
CA002322435A CA2322435A1 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
IL138207??A IL138207A0 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
HU0101076A HUP0101076A2 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
JP2000534186A JP2003523308A (en) 1998-03-02 1999-03-02 Methods and devices for modulating an immune response
KR1020007009699A KR20010041528A (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
AU30667/99A AU756951B2 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response
NO20004349A NO20004349L (en) 1998-03-02 2000-09-01 Methods and devices for modulating the immune response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3340298A 1998-03-02 1998-03-02
US09/033,402 1998-03-02

Publications (2)

Publication Number Publication Date
WO1999044583A2 WO1999044583A2 (en) 1999-09-10
WO1999044583A3 true WO1999044583A3 (en) 1999-11-11

Family

ID=21870212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/004637 WO1999044583A2 (en) 1998-03-02 1999-03-02 Methods and devices for modulating the immune response

Country Status (4)

Country Link
BR (1) BR9908466A (en)
CA (1) CA2322435A1 (en)
IL (1) IL138207A0 (en)
WO (1) WO1999044583A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
EP1387670B1 (en) 2001-05-11 2008-10-15 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Immune modulation device for use in animals
AU2003231234A1 (en) * 2002-05-03 2003-11-17 Children's Hospital Medical Center Simulated vernix compositions for skin cleansing and other applications
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
CN102006891B (en) 2008-02-13 2017-04-26 哈佛学院董事会 Continuous cell programming devices
PT2624873T (en) 2010-10-06 2020-03-04 Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
ES2773895T3 (en) 2012-04-16 2020-07-15 Harvard College Mesoporous Silica Compositions to Modulate Immune Responses
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College Peritumoral and intratumoral materials for cancer therapy
CN107708756A (en) 2015-04-10 2018-02-16 哈佛学院院长等 Immunocyte acquisition equipment and its preparation and application
EP3411475A4 (en) 2016-02-06 2019-09-11 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732155A (en) * 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
EP0300102A1 (en) * 1987-07-21 1989-01-25 The Stolle Research And Development Corporation Improved method of obtaining immune regulatory factors by mammal immunization
US4919929A (en) * 1984-02-01 1990-04-24 Stolle Research & Development Corporation Mammal immunization
WO1993017662A1 (en) * 1992-03-02 1993-09-16 Daratech Pty. Ltd. Improved implants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919929A (en) * 1984-02-01 1990-04-24 Stolle Research & Development Corporation Mammal immunization
US4732155A (en) * 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
EP0300102A1 (en) * 1987-07-21 1989-01-25 The Stolle Research And Development Corporation Improved method of obtaining immune regulatory factors by mammal immunization
WO1993017662A1 (en) * 1992-03-02 1993-09-16 Daratech Pty. Ltd. Improved implants

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery

Also Published As

Publication number Publication date
WO1999044583A2 (en) 1999-09-10
BR9908466A (en) 2000-12-05
CA2322435A1 (en) 1999-09-10
IL138207A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
WO1999044583A3 (en) Methods and devices for modulating the immune response
EP0692952A1 (en) Method for implanting tissue in a host
EP1025856A3 (en) Methods for modulating T Cell unresponsiveness
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
MXPA01007657A (en) Non-invasive vaccination through the skin.
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
AU645552B2 (en) Idiotypic vaccination against B cell lymphoma
HK1053333A1 (en) Epitope synchronization in antigen presenting cells
WO2000061184A3 (en) Dry formulation for transcutaneous immunization
WO2002034205A3 (en) Using heat shock proteins to increase immune response
EP0284409A3 (en) Active specific immune suppression
EP0313378A3 (en) Methods and compositions for transient elimination of humoral immune antibodies
AU4396401A (en) Composition and method for the prevention and/or the treatment of allergy
TR200003225T2 (en) Methods and tools to modulate the immune response
AU605159B2 (en) Improved mammal immunization
RU2000124880A (en) METHODS AND DEVICES FOR IMMUNE RESPONSE MODULATION
EP0317622A4 (en) Prevention and treatment of retroviral disease.
NZ554142A (en) Antibody production method comprising inserting antigen releasing device into mammal so antibodies are released into its milk
WO2002043651A8 (en) Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
WO2003057823A3 (en) Epitope synchronization in antigen presenting cells
WO2001043772A3 (en) Method and device for producing an autologous immunization vaccine against cancerous diseases (tumour vaccine)
Uchida et al. IgE-specific unresponsiveness in mice induced by ovalbumin coupled with murine red blood cells
WO2001034192A3 (en) Improved method of immunization
Wilhelm SEROLOGICAL AND BIOLOGICAL STUDIES ON A RAT CARCINOEMBRYONIC ANTIGEN.
De Weck An explanation of the mode of action of Gynatren/Solco Trichovac based on immunological considerations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99805765.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/008532

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2322435

Country of ref document: CA

Ref document number: 2322435

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 138207

Country of ref document: IL

Ref document number: PV2000-3206

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020007009699

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 534186

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 506786

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 30667/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2000/445/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1999912252

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2000/03225

Country of ref document: TR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999912252

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007009699

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-3206

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 30667/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020007009699

Country of ref document: KR